Syndecan-1 in the Tumor Microenvironment

被引：7
|
作者：
Handra-Luca, Adriana [1 ,2 ]
机构：
[1] Univ Sorbonne Paris Nord, Serv Anat Pathol, Bobigny, France
[2] Univ Sorbonne Paris Nord, APHP GHU Avicenne, Bobigny, France
来源：
TUMOR MICROENVIRONMENT: EXTRACELLULAR MATRIX COMPONENTS - PT B | 2020年 / 1272卷
关键词：
Syndecan-1; Tumor; Stroma; Microenvironment; Pathology; Microscopy; Immunohistochemistry; Fibroblast; Vessels; Inflammatory cells; Extracellular matrix; Adenocarcinoma; Squamous cell carcinoma; Morphotype; Prognosis; STROMAL FIBROBLASTS; PROGNOSTIC VALUE; EXPRESSION; CELLS; CARCINOMAS; MYELOMA;
D O I：
10.1007/978-3-030-48457-6_3
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Syndecan-1 along with the other three syndecan proteins is present in the varied components of the tumor microenvironment: fibroblasts, inflammatory tumor immunity-associated cells, vessels, and extracellular matrix. Epithelial and non-epithelial tumors may show stromal syndecans. The main relevance of stromal syndecans as tumor biomarker resides in the relationships to tumor features such as type and differentiation as well as to prognosis.
引用
收藏
页码：39 / 53
页数：15
相关论文
共 50 条
  • [41] INTERACTIONS OF SYNDECAN-1 AND HEPARIN WITH HUMAN COLLAGENS
    SANANTONIO, JD
    KARNOVSKY, MJ
    GAY, S
    SANDERSON, RD
    LANDER, AD
    GLYCOBIOLOGY, 1994, 4 (03) : 327 - 332
  • [42] Syndecan-1 expression in human glioma is correlated with advanced tumor progression and poor prognosis
    Xu, Yimin
    Yuan, Jun
    Zhang, Ziheng
    Lin, Lvbiao
    Xu, Shengliang
    MOLECULAR BIOLOGY REPORTS, 2012, 39 (09) : 8979 - 8985
  • [43] Low Soluble Syndecan-1 Precedes Preeclampsia
    Gandley, Robin E.
    Althouse, Andrew
    Jeyabalan, Arundhathi
    Bregand-White, Julia M.
    McGonigal, Stacy
    Myerski, Ashley C.
    Gallaher, Marcia
    Powers, Robert W.
    Hubel, Carl A.
    PLOS ONE, 2016, 11 (06): : 1 - 18
  • [44] The endothelial glycocalyx in syndecan-1 deficient mice
    Savery, Michele D.
    Jiang, John X.
    Park, Pyong Woo
    Damiano, Edward R.
    MICROVASCULAR RESEARCH, 2013, 87 : 83 - 91
  • [45] Altered expression of syndecan-1 in prostate cancer
    Kiviniemi, J
    Kallajoki, K
    Kujala, I
    Matikainen, MT
    Alanen, K
    Jalkanen, M
    Salmivirta, M
    APMIS, 2004, 112 (02) : 89 - 97
  • [46] Soluble Endoglin and Syndecan-1 levels predicts the clinical outcome in COVID-19 patients
    Rajan, Remya
    Hanifah, Mohamed
    Mariappan, Vignesh
    Anand, Monica
    Pillai, Agieshkumar Balakrishna
    MICROBIAL PATHOGENESIS, 2024, 188
  • [47] Expression of syndecan-1, PKC and VEGF n rats with acute kidney injury and correlation between syndecan-1 and renal function
    Qin, L-L
    Xue, F.
    Yin, F.
    Zhao, J.
    Zhang, K-Y
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (24) : 12794 - 12801
  • [48] Utility of CD138/syndecan-1 immunohistochemistry for localization of plasmacytes is tissue-dependent in B6 mice
    Meyerholz, David K.
    Leidinger, Mariah R.
    Goeken, J. Adam
    Businga, Thomas R.
    Akers, Allison
    Vizuett, Sebastian
    Kaemmer, Courtney A.
    Kohlmeyer, Jordan L.
    Dodd, Rebecca D.
    Quelle, Dawn E.
    BMC RESEARCH NOTES, 2022, 15 (01)
  • [49] Syndecan-1 expression has prognostic significance in head and neck carcinoma
    A Anttonen
    M Kajanti
    P Heikkilä
    M Jalkanen
    H Joensuu
    British Journal of Cancer, 1999, 79 : 558 - 564
  • [50] Orthotopic pancreatic tumors detected by optoacoustic tomography using Syndecan-1
    Kimbrough, Charles W.
    Hudson, Shanice
    Khanal, Anil
    Egger, Michael E.
    McNally, Lacey R.
    JOURNAL OF SURGICAL RESEARCH, 2015, 193 (01) : 246 - 254
12345